SGLT-2 inhibitors, also called gliflozins, are a new class of drugs used in type 2 diabetes. Since their marketing, several cases of ketoacidosis, including life-threatening conditions, were reported with their use. The objective of this study was to investigate the disproportionality of pharmacovigilance reports of ketoacidosis between gliflozins and other drugs used for type 2 diabetes. We performed a case-noncase study within the World Health Organization's pharmacovigilance database, VigiBase. We selected all reports of serious adverse drug reaction associated with a glucose-lowering drug in patients aged 40 years and older, from January 2013 to March 2016. Cases were the reports of ketoacidosis and noncases were all other serious adverse drug reactions reported. We studied the disproportionality of reports of ketoacidosis for gliflozins by calculating reporting odds ratios (ROR) with their 95% confidence interval (95% CI). We also measured the disproportionality before the warnings issued by the US and European medicines agencies. A total of 68 555 notifications were selected. We identified 487 cases of ketoacidosis exposed to gliflozins. Ketoacidosis was significantly more frequently reported with gliflozins than with other glucose-lowering drugs (adjusted ROR 15.5; 95% CI: 12.8-18.7). The disproportionality of gliflozin reports was also found before the alerts of the medicines agencies. Our study shows a significant and early pharmacovigilance signal which suggests an increased risk of ketoacidosis associated with the use of gliflozins in patients with diabetes. Further studies are needed to confirm this potential risk.
Keywords: SGLT-2 inhibitors; adverse drug reactions; disproportionality analysis; gliflozins; ketoacidosis.
© 2017 Société Française de Pharmacologie et de Thérapeutique.